tiprankstipranks
Clover Health Investments (DE:7QD)
FRANKFURT:7QD
Germany Market
7QD
Clover Health Investments
RESEARCH TOOLSreports

Clover Health Investments (7QD) Stock Forecast & Price Target

0 Followers
See the Price Targets and Ratings of:

7QD Analyst Ratings

Moderate Buy
2Ratings
Moderate Buy
1 Buy
1 Hold
0 Sell
Based on 2 analysts giving stock ratings to
Clover
Health Investments
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

7QD Stock 12 Month Forecast

Average Price Target

€4.54
▲(16.48% Upside)
Based on 2 Wall Street analysts offering 12 month price targets for Clover Health Investments in the last 3 months. The average price target is €4.54 with a high forecast of €4.76 and a low forecast of €4.33. The average price target represents a 16.48% change from the last price of €3.90.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"€0","5":"€5","1.25":"€1.25","2.5":"€2.5","3.75":"€3.75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":4.759131685,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€4.76</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":4.5428075175,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€4.54</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":4.32648335,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€4.33</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,1.25,2.5,3.75,5],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.68,3.7630101296153846,3.8460202592307695,3.929030388846154,4.012040518461538,4.095050648076923,4.178060777692307,4.261070907307692,4.344081036923077,4.427091166538461,4.510101296153846,4.593111425769231,4.676121555384615,{"y":4.759131685,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.68,3.7463698090384616,3.812739618076923,3.8791094271153845,3.9454792361538464,4.0118490451923075,4.078218854230769,4.144588663269231,4.210958472307692,4.277328281346154,4.343698090384615,4.410067899423077,4.476437708461539,{"y":4.5428075175,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.68,3.7297294884615386,3.779458976923077,3.8291884653846155,3.878917953846154,3.9286474423076925,3.978376930769231,4.028106419230769,4.077835907692307,4.127565396153846,4.177294884615385,4.227024373076923,4.276753861538461,{"y":4.32648335,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":2.445,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.173,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.547,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.96,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.073,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.042,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.86,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.716,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.475,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.15,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.35,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.51,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.68,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target€4.76Average Price Target€4.54Lowest Price Target€4.33
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Canaccord Genuity Analyst forecast on DE:7QD
Richard Close
Canaccord Genuity
Canaccord Genuity
€4.76
Buy
22.03%
Upside
Reiterated
08/06/26
Clover Health Investments (CLOV) Receives a Buy from Canaccord Genuity
UBS Analyst forecast on DE:7QD
Jonathan Yong
UBS
UBS
€4.11→€4.33
Hold
10.94%
Upside
Reiterated
08/06/26
UBS Sticks to Their Hold Rating for Clover Health Investments (CLOV)
Leerink Partners Analyst forecast on DE:7QD
Whit Mayo
Leerink Partners
Leerink Partners
€2.16→€2.6
Hold
-33.44%
Downside
Reiterated
10/22/25
Clover Health Investments (CLOV) Gets a Hold from Leerink Partners
Craig-Hallum Analyst forecast on DE:7QD
Matt Hewitt
Craig-Hallum
Craig-Hallum
―
Buy
―
Reiterated
10/10/25
Craig-Hallum Sticks to Their Buy Rating for Clover Health Investments (CLOV)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Canaccord Genuity Analyst forecast on DE:7QD
Richard Close
Canaccord Genuity
Canaccord Genuity
€4.76
Buy
22.03%
Upside
Reiterated
08/06/26
Clover Health Investments (CLOV) Receives a Buy from Canaccord Genuity
UBS Analyst forecast on DE:7QD
Jonathan Yong
UBS
UBS
€4.11→€4.33
Hold
10.94%
Upside
Reiterated
08/06/26
UBS Sticks to Their Hold Rating for Clover Health Investments (CLOV)
Leerink Partners Analyst forecast on DE:7QD
Whit Mayo
Leerink Partners
Leerink Partners
€2.16→€2.6
Hold
-33.44%
Downside
Reiterated
10/22/25
Clover Health Investments (CLOV) Gets a Hold from Leerink Partners
Craig-Hallum Analyst forecast on DE:7QD
Matt Hewitt
Craig-Hallum
Craig-Hallum
―
Buy
―
Reiterated
10/10/25
Craig-Hallum Sticks to Their Buy Rating for Clover Health Investments (CLOV)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
AVBPArriVent BioPharma, Inc.
BTSGBrightSpring Health Services, Inc.
ZURAZura Bio
TNYATenaya Therapeutics
JBIOJade Biosciences
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Clover Health Investments

3 Months
Richard CloseCanaccord Genuity
Success Rate
15/26 ratings generated profit
58%
Average Return
+20.58%
Copying Richard Close's trades and holding each position for 3 Months would result in 57.69% of your transactions generating a profit, with an average return of +20.58% per trade.
1 Year
Richard CloseCanaccord Genuity
Success Rate
15/26 ratings generated profit
58%
Average Return
+63.72%
Copying Richard Close's trades and holding each position for 1 Year would result in 57.69% of your transactions generating a profit, with an average return of +63.72% per trade.
2 Years
Richard CloseCanaccord Genuity
Success Rate
24/26 ratings generated profit
92%
Average Return
+92.40%
Copying Richard Close's trades and holding each position for 2 Years would result in 92.31% of your transactions generating a profit, with an average return of +92.40% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

7QD Analyst Recommendation Trends

Rating
Apr 26
May 26
Jun 26
Jul 26
Aug 26
Strong Buy
2
1
0
0
0
Buy
0
1
2
3
3
Hold
1
0
1
1
2
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
3
2
3
4
5
In the current month, 7QD has received 3 Buy Ratings, 2 Hold Ratings, and 0 Sell Ratings. 7QD average Analyst price target in the past 3 months is 4.54.
Each month's total comprises the sum of three months' worth of ratings.

7QD Financial Forecast

7QD Earnings Forecast

Next quarter’s earnings estimate for 7QD is <€0.01 with a range of >-€0.01 to <€0.01. The previous quarter’s EPS was €0.06. 7QD beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.20% of the time in the same period. In the last calendar year 7QD has Performed in-line its overall industry.
Next quarter’s earnings estimate for 7QD is <€0.01 with a range of >-€0.01 to <€0.01. The previous quarter’s EPS was €0.06. 7QD beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.20% of the time in the same period. In the last calendar year 7QD has Performed in-line its overall industry.

7QD Sales Forecast

Next quarter’s sales forecast for 7QD is €632.29M with a range of €624.74M to €642.53M. The previous quarter’s sales results were €643.06M. 7QD beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.28% of the time in the same period. In the last calendar year 7QD has Performed in-line its overall industry.
Next quarter’s sales forecast for 7QD is €632.29M with a range of €624.74M to €642.53M. The previous quarter’s sales results were €643.06M. 7QD beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.28% of the time in the same period. In the last calendar year 7QD has Performed in-line its overall industry.

7QD Stock Forecast FAQ

What is DE:7QD’s average 12-month price target, according to analysts?
Based on analyst ratings, Clover Health Investments’s 12-month average price target is 4.54.
    What is DE:7QD’s upside potential, based on the analysts’ average price target?
    Clover Health Investments has 16.48% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is Clover Health Investments a Buy, Sell or Hold?
          Clover Health Investments has a consensus rating of Moderate Buy, which is based on 1 buy ratings, 1 hold ratings and 0 sell ratings.
            What is Clover Health Investments’s share price target?
            The average share price target for Clover Health Investments is 4.54. This is based on 2 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is €4.76 ,and the lowest forecast is €4.33. The average share price target represents 16.48% Increase from the current price of €3.9.
              What do analysts say about Clover Health Investments?
              Clover Health Investments’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 2 Wall Streets Analysts.
                How can I buy shares of Clover Health Investments?
                To buy shares of DE:7QD, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.